Meeting with Fresenius Kabi

Brussels – Commission premises, 22/02/2024, 11:30

Participants

- [redacted], Fresenius Kabi
- [redacted], Fresenius Kabi
- [redacted] Fresenius Kabi

- Kristin Schreiber, DG GROW
- [redacted] DG GROW
- [redacted], DG GROW

Notes

- COM welcome and tour de table
- Fresenius Kabi gave a short introduction of the company. Fresenius Kabi is a global healthcare company that specialises in lifesaving medicines and technologies for infusion, transfusion, clinical nutrition and biosimilars. The product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Fresenius Kabi employs more than 190,000 people worldwide, €21.5 billion in annual revenue. European production facilities located in France, Germany, Italy, Spain, Portugal, Austria, Sweden and Poland.
- Fresenius Kabi is concerned with respect to the PFAS restriction as currently assessed by ECHA. Fresenius Kabi indicated that they do not know for every product if PFAS is used or not. Registration of all products will take time. In the past, Fresenius Kabi moved away from PVC (with DEHP) in their infusion materials to multilayer plastic materials. Products in the EU are fulfilling high technical and environmental standards.
- COM informed that the Commission is aware of critical uses of PFAS and indicated that derogations will be granted if no alternatives are available.
- Fresenius Kabi asked about the foreseen REACH revision. COM replied that the REACH revision will be discussed under the next mandate of the Commission.
- Fresenius Kabi explained recent developments on biosimilar medicines. The development of biosimilar is very complicated compared to regular chemical medicines.